Treace Medical Concepts, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TMCI research report →
Range $6.5 – $6.5
Price Chart
About the company
Treace Medical Concepts, Inc. , a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
- CEO
- John T. Treace
- IPO
- 2021
- Employees
- 450
- HQ
- Ponte Vedra, FL, US
Get TickerSpark's AI analysis on TMCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $282.56M
- P/E
- -5.01
- PEG
- 0.47
- P/S
- 1.39
- P/B
- 4.58
- EV/EBITDA
- -7.94
- Div Yield
- 0.00%
- Gross Margin
- 79.55%
- Op Margin
- -24.38%
- Net Margin
- -27.44%
- ROE
- -75.93%
- ROIC
- -35.62%
Latest fiscal year · YoY change
- Revenue
- $212.69M+1.6%
- Gross Profit
- $169.75M+0.9%
- Op Income
- $-54,154,000
- Net Income
- $-59,002,000-5.8%
- EPS
- $-0.93-3.3%
- OCF Growth
- +57.0%
- FCF Growth
- +39.5%
- 52W High
- $5.44
- 52W Low
- $1.17
- 50D MA
- $4.42
- 200D MA
- $3.39
- Beta
- 1.56
- RSI (14)
- 46
- Avg Volume
- 267.81K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Treace Medical said third-quarter revenue fell on mix and distributor timing, but procedure growth, broader product adoption, and new launches gave management confidence in a return to growth in Q4 and continued margin/cash improvement.· November 6, 2026
- Q3 revenue was $48.3 million, down 4% year over year, but ex stocking-distributor orders bunion kit sales volume grew mid-single digits.
- Gross margin was 79.5% vs. 79.1% last year; adjusted EBITDA turned positive at $300 thousand from a $2.6 million loss.
- Full-year 2026 revenue guidance was narrowed to $206 million-$210 million, and management expects Q4 revenue growth to return.
- The company highlighted a roughly $700 million TAM expansion from 2026 product introductions and another $400 million from SuperBite, HyperPlate XM, Vitafuse, and CartiBlaster.
- Adoption of the 2025 bunion systems is expanding: about 45% of Lapiplasty surgeons used at least one of the new systems, up from 40% in Q2.
Third-quarter 2026 revenue was $48.3 million, down 4% from the prior-year period. Gross margin was 79.5% versus 79.1% in Q3 2025. Net loss improved to $12.6 million, or $0.19 per share, from $16.3 million, or $0.26 per share, a year ago. Adjusted EBITDA was positive $300 thousand versus a loss of $2.6 million in Q3 2025. Total operating expenses fell 10% to $49.9 million from $55.4 million. Year to date cash usage was reduced by 53%, or $9.7 million, and cash, cash equivalents, and marketable securities were $39.8 million at September 30, 2026. For full-year 2026, revenue guidance was narrowed to $206 million-$210 million, implying a decline of 3% to 1% versus 2025, and adjusted EBITDA loss guidance was updated to $1 million-$2 million. Management reiterated cash usage should fall about 50% year over year and expects revenue growth to resume in Q4 as procedure volumes rise, distributor headwinds fade, and 2025/2026 launches contribute.
John T. Treace emphasized that the quarter validated the company’s strategy: double-digit case volume growth, broader adoption of new bunion systems, and expansion into adjacent foot and ankle procedures. He framed Treace as building a larger diversified business around its Lapiplasty anchor, with new technologies expected to broaden the addressable market and deepen wallet share among existing surgeons. His tone was upbeat but measured, repeatedly stressing disciplined execution, training, and maintaining focus on the core bunion franchise while rolling out new products.
Mark L. Hair focused on the revenue mix shift and the improving profitability profile. He said Q3 revenue was pressured mainly by lower-priced minimally invasive products and lower bunion kit volume, but excluding stocking distributors, bunion kit sales volume increased and revenue grew mid-single digits. He also highlighted gross margin of 79.5%, operating expenses down $5.5 million to $49.9 million, a smaller net loss of $12.6 million, positive adjusted EBITDA of $300 thousand, reduced year-to-date cash usage by 53% or $9.7 million, and cash of $39.8 million. On guidance, he reiterated 2026 revenue of $206 million-$210 million, adjusted EBITDA loss of $1 million-$2 million, and roughly 50% lower cash usage for the year.
Analysts pressed on ASP pressure versus volume growth, the cadence of adoption for the new bunion systems, international expansion, Q4 phasing, and whether the broader portfolio would require materially more sales headcount. Management said ASPs may remain under pressure as lower-priced MIS products grow, but higher-ASP complex midfoot/hindfoot cases are also entering the mix. They said adoption among existing surgeons is still early, with roughly 45% using at least one of the three 2025 bunion systems and repeat/reorder behavior looking healthy; international is an opportunity but not yet material; and rep additions should be incremental rather than large-scale. They also said Q4 should benefit from seasonality and lower distributor headwinds, supporting a return to growth.
The bull case is that Treace is showing real procedure growth even while revenue is temporarily mixed by ASP and distributor timing, and management expects those headwinds to ease in Q4. The company is also expanding its footprint beyond Lapiplasty with new products that management says could widen TAM by about $1.1 billion combined across the 2026 portfolio additions, while improving leverage and cash usage.
The main risks are that revenue is still down year over year, ASPs may keep compressing as the mix shifts toward lower-priced products, and management has not yet proven that the new launches can fully offset that effect. Analysts also raised concern about how quickly adoption can scale, whether the portfolio expansion strains the sales force, and whether the company can convert the current momentum into sustained growth beyond the seasonally strong fourth quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 73.3%
- Shares Outstanding
- 65.56M
- Float Shares
- 48.05M
of shares held by institutions
122 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 6.36M | 0 |
| Gagnon Securities LLC | 3.42M | ▲ 386.38K |
| Bank Of America Corp | 3.26M | ▼ 40.19K |
| Vanguard Group Inc | 2.27M | ▼ 458.39K |
| Vanguard Capital Management LLC | 2.06M | ▲ 30.41K |
| Gagnon Advisors, LLC | 1.53M | 0 |
| Cibc Private Wealth Group LLC | 1.48M | ▼ 207.69K |
| Acadian Asset Management LLC | 1.35M | ▲ 426.29K |
| Blackrock, Inc. | 1.31M | ▼ 69.60K |
| Millennium Management LLC | 1.25M | ▲ 508.17K |
| Marshall Wace, Llp | 1.25M | ▼ 82.39K |
| Cibc Bancorp Usa Inc. | 1.22M | ▼ 124 |
Held by 55 ETFs
Biggest fund positions in TMCI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 24, 26 | Scanlan Sean F. | other | 207 |
| Sep 30, 26 | Elder Scot Michael | other | 25,457 |
| Aug 24, 26 | Treace John T. | buy | 11,000 |
| Aug 21, 26 | Treace John T. | buy | 5,000 |
| Aug 20, 26 | Treace John T. | buy | 39,944 |
| Aug 9, 26 | Scanlan Sean F. | other | 9,814 |
| Aug 9, 26 | Hair Mark | other | 37,102 |
| Aug 9, 26 | Elder Scot Michael | other | 16,253 |
| Jun 11, 26 | Treace John T. | buy | 9,891 |
| Jun 10, 26 | Treace John T. | buy | 14,715 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TMCI coverage
Recent articles, reports, and earnings notes.
No research on TMCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TMCI report →Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Average Price Target of $6.17 According to Analysts
defenseworld.net · Nov 19
Treace Medical Concepts, Inc. (TMCI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 6
Treace Medical Concepts Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 6
Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor's Bunion Correction System
globenewswire.com · Nov 6
Treace to Present at the Stifel 2026 Healthcare Conference
globenewswire.com · Nov 3
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
globenewswire.com · Oct 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.